Podcasts

Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.

Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.

Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses their approach to orphan drug development, challenges and opportunities adapting to the US market, and more.

Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.

Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts, alternative solutions to ensure continued access to medications for all Americans, potential long term consequences if these pharmacy closures continue, and more

Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.

Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.

A Frost & Sullivan industry-wide survey reveals which insights most pharmaceutical companies have mastered and which are still painful or impossible to extract and details the complexity of the process, the confidence companies have in their findings, and more. Hear Web Sun, President and Co-founder of Komodo Health, share what's driving these challenges and how you can overcome them.

In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract Gen-Z.

In an interview with PharmExec Associate Editor Don Tracy, Jingsong Wang discusses Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033.

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.

Michael Shaw, JD, and Sharon Suchotliff, MPH, from ZS, discuss why measuring impact through a patient-centric lens is a business imperative for life sciences companies. They explore key considerations for a key challenge when thinking about impact for patients in the real world- the compliant measurement of non-promotional activities, results from an early ZS proof of concept to determine Patient Outcomes Impact (POI™) metrics, and discuss what you can do today to advance POI™ at your organization.

Sameer Lal, Sr. Vice President, Enterprise Medical Solutions at Indegene, discusses findings from their new study about Reshaping Pharmacovigilance in the age of AI, digital/generative AI opportunities, how quickly the industry is adopting this technology, and much more.

Explore the implementation of enterprise laboratory software and the start of a digital transformation in your lab with an industry expert who discusses maximizing returns on investment, upholding data integrity while managing cost containment, and adopting digital best practices. This podcast addresses critical topics such as cybersecurity, regulatory compliance and fiscal strategy for pharmaceutical labs and offers valuable insights for professionals at the crossroads of technology, finance, and pharmaceutical regulations. Discover how laboratories can use software solutions to surpass industry standards while managing costs with Bob Voelkner, Vice President, Sales and Marketing, LabVantage Solutions, Inc.

A discussion of the current standard for diabetes care and how the importance of patient centricity, including addressing patient's mental health, are imperative to the future of the space.

MilliporeSigma’s Stephen Wing, head of Analytical and Logistical Services, discusses the ways in which digital transformation and data transparency dramatically enhance supply chains, and how manufacturers are using the company’s eMERGE™ platform to improve overall efficiencies.

A discussion of the biggest digital trends in clinical research, how COVID-19 impacted digital use for sponsors/CROs, what the future of DCT services looks like, and more.

A discussion of the impact the new FDA SaMD guidance, identifying the differences between companion apps and SaMD, and what to expect from this combination in the future.

An expert from Flagship Pioneering, the venture creation firm behind Moderna and other life science firms, shares the process of founding a company, how they decide whether to partner with companies, the importance of collaboration and how they approach it, and where science is booming in pharma right now.

Lung-I Cheng, vice president of cell and gene therapy (CGT), Cencora (formerly AmerisourceBergen), discusses CGT commercialization strategies, common knowledge gaps, and what he wishes companies knew about commercialization strategies.

In this Pharm Exec Podcast episode, Gerald Kierce, co founder and CEO of Trustible, and Andrew Camino Chung, the company's CTO and co founder, delve into the realm of artificial intelligence, discussing Trustible's mission and its pioneering efforts to ensure ethical AI use, particularly in the pharmaceutical industry, and how it navigates complex AI regulations across the globe.

In this Pharm Exec Podcast episode, Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, discusses the biggest drug pricing challenges today, what companies should consider for drug pricing (from a legal perspective), the status and potential impact of the Inflation Reduction Act, and drug pricing recommendations.

This podcast companion to our roundtable feature explores the transformative power of AI in pharmaceutical marketing, six months after the arrival of ChatGPT.

Sharon Suchotliff, associate principal at ZS and lead for patient centricity, discusses why patient centricity has become a business imperative for life sciences companies. Sharon delves into the measurement of patient centricity, provides examples of how different companies have approached this and ZS’s approach for Patient Outcomes Impact (POI).

Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.

Senior editor Fran Pollaro chats with Sharlene Jenner, vice president of engagement strategy, Abelson Taylor about the transformative impact and ethical considerations of AI in the pharmaceutical industry, emphasizing its potential in data analysis and marketing, while also highlighting the pioneering work of AI companies in advancing drug discovery.

HBA mentor of the year and director of U.S. public affairs for AbbVie, Jag Dosanjh, divulges in this Pharm Exec Podcast his approach to leadership and how: “If you listen well, you can learn well.”

Senior editor Fran Pollaro and Morten Nielsen, senior partner for the life sciences practice at Wittkieffer, embark on an insightful exploration of trust in the pharmaceutical industry, discussing its measurement, improvement, and critical role in governance, culture, leadership, and organizational structure, while offering practical advice for industry leaders on embedding transparency, inclusion, and accountability into daily operations.

The 2023 Emerging Pharma Leaders share with the Pharmaceutical Executive editors what makes a good leader, what has made them the proudest in their career, lessons they wish they had known when starting out, and more. (This is the audio-only Pharm Exec Podcast episode!)